Today BNTX tanked \~20% because SMMT's (down \~40%) results for their drug Ivonescimab wasn't as good as expected.
My naive reading is that this BNTX selloff was a knee jerk reaction because they also have a similar drug in the pipeline.
However, according to this press release ([https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-and-preclinical-data-across-mrna-and](https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-and-preclinical-data-across-mrna-and)), BNTX will release results at a conference **THIS WEEKEND** related to that drug **BNT327**
They frame these as **HIGHLIGHTS** so I don't think they would be negative. That actually seems great for BNTX as their competitor SMMT's drug didn't perform to expectations.
**Highlights of BioNTech’s oncology programs to be presented at AACR 2025:**
* BioNTech will present preclinical data characterizing the mode of action of **BNT327**. BNT327 is an investigational next-generation bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization. BNT327 showed a high binding affinity to PD-L1 and VEGF-A and efficient blocking of PD-1/PD-L1 and VEGF-A/VEGFR2 signaling. Anti-tumor activity superior to single PD-1/PD-L1 blockade or anti-VEGF-A treatment was observed in multiple tumor models.
* First data for the combination of **BNT327 with various ADC candidates**, which are being jointly developed by BioNTech and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), will be presented. The presentation will include preclinical evaluation of BNT327 plus ADCs, showing inhibition of tumor growth that is superior to each candidate alone. Further, early clinical data of the ongoing global Phase 1/2 trial ([NCT05438329](https://clinicaltrials.gov/study/NCT05438329)) of BNT327 in combination with **BNT325/DB-1305**, a TROP2-targeting ADC candidate, including safety and early efficacy
BNTX is presenting their results on **Sunday, Apr 27** and **Tue, Apr 29**. If the results are good as promised, the stock should shoot up 20%+
TLDR; Buy short dated BNTX options